VKTX Viking Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1607678 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-164.2%
TTM EPS YoY-155.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-96.4%
ROA-73.1%
ROIC (approx.)-195.7%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets39.8%
Debt / equity0.00x
Current ratio7.27x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.74x
Accruals ratio-19.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $344.95M | $101.64M | $63.81M | $54.23M | $44.98M |
| SG&A expense | $48.39M | $49.28M | $37.02M | $16.12M | $10.70M |
| Operating income | -$393.34M | -$150.92M | -$100.83M | -$70.36M | -$55.68M |
| Pretax income | -$359.64M | -$109.96M | -$85.89M | — | — |
| Income tax | $1,000 | $1,000 | $1,000 | $1,000 | $2,000 |
| Net income | -$359.64M | -$109.96M | -$85.89M | -$68.87M | -$54.99M |
| EPS (basic) | -3.19 | -1.01 | -0.91 | -0.90 | -0.71 |
| EPS (diluted) | -3.19 | -1.01 | -0.91 | -0.90 | -0.71 |
| Weighted avg. shares (diluted) | 112.67M | 109.04M | 94.35M | 76.83M | 77.20M |
| Balance sheet | |||||
| Cash & equivalents | $165.81M | $26.68M | $55.52M | $36.63M | $26.37M |
| Short-term investments | $539.93M | $875.94M | $306.56M | $118.85M | $175.73M |
| Current assets | $715.60M | $907.22M | $367.23M | $167.04M | $210.53M |
| Total assets | $715.73M | $908.32M | $368.49M | $168.53M | $210.66M |
| Current liabilities | $76.67M | $27.41M | $19.14M | $21.95M | $8.78M |
| Total liabilities | $76.67M | $28.04M | $20.07M | $23.21M | $8.78M |
| Shareholders' equity | $639.06M | $880.28M | $348.42M | $145.32M | $201.88M |
| Shares outstanding | 114.79M | 111.57M | 100.11M | 78.26M | 78.25M |
| Cash flow statement | |||||
| Operating cash flow | -$278.69M | -$87.79M | -$73.38M | -$48.40M | -$47.59M |
| Investing cash flow | $341.39M | -$553.37M | -$179.09M | $54.75M | $37.96M |
| Financing cash flow | $76.44M | $612.46M | $271.38M | $4.16M | $6.88M |
| Stock-based compensation | $40.82M | $29.71M | $16.75M | $8.67M | $6.10M |
| Share buybacks | — | — | — | $6.79M | — |
Free plan shows the latest 5 periods; Pro shows all 12 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.